Success Metrics

Clinical Success Rate
73.3%

Based on 11 completed trials

Completion Rate
73%(11/15)
Active Trials
4(15%)
Results Posted
27%(3 trials)
Terminated
4(15%)

Phase Distribution

Ph not_applicable
4
15%
Ph early_phase_1
1
4%
Ph phase_3
7
27%
Ph phase_2
4
15%
Ph phase_1
3
12%
Ph phase_4
5
19%

Phase Distribution

4

Early Stage

4

Mid Stage

12

Late Stage

Phase Distribution24 total trials
Early Phase 1First-in-human
1(4.2%)
Phase 1Safety & dosage
3(12.5%)
Phase 2Efficacy & side effects
4(16.7%)
Phase 3Large-scale testing
7(29.2%)
Phase 4Post-market surveillance
5(20.8%)
N/ANon-phased studies
4(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

61.1%

11 of 18 finished

Non-Completion Rate

38.9%

7 ended early

Currently Active

4

trials recruiting

Total Trials

26

all time

Status Distribution
Active(4)
Completed(11)
Terminated(7)
Other(4)

Detailed Status

Completed11
Recruiting4
unknown4
Terminated4
Withdrawn3

Development Timeline

Analytics

Development Status

Total Trials
26
Active
4
Success Rate
73.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (4.2%)
Phase 13 (12.5%)
Phase 24 (16.7%)
Phase 37 (29.2%)
Phase 45 (20.8%)
N/A4 (16.7%)

Trials by Status

recruiting415%
withdrawn312%
unknown415%
completed1142%
terminated415%

Recent Activity

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT05056220Phase 3

Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

Recruiting
NCT06911554Phase 3

A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites

Completed
NCT05895136Phase 2

A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

Recruiting
NCT03214796

Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status

Completed
NCT06630923Phase 3

PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS

Recruiting
NCT04540094Phase 3

Feasibility of 5% Albumin Compared With Balanced Crystalloid, as Intravenous Fluid Resuscitation in Adult Patients With Sepsis, Presenting as an Emergency to Hospital

Completed
NCT06548477Not Applicable

Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages

Recruiting
NCT05645887Phase 2

Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.

Withdrawn
NCT06126354Phase 1

Dexamethasone/Pancreatic Clamp P&F

Withdrawn
NCT06411743Phase 2

Phase II/III of Recombinant Human Albumin Injection

Completed
NCT02882074Not Applicable

Endothelial Function After Cardiac Surgery

Completed
NCT04418739Phase 2

Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes

Unknown
NCT03167645Phase 4

SUbstition of PERioperative Albumin Deficiency Disorders

Completed
NCT04490668

Human Albumin and Anastomotic Leakage After Gastric Cancer Surgery

Completed
NCT02613052Not Applicable

Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations

Completed
NCT01822600Phase 4

The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia

Completed
NCT03950778Early Phase 1

The Effect of Albumin Supplementation on the Inflammatory and Oxidative Stress Markers in Septic Patients

Unknown
NCT01849757Not Applicable

Comparison of Priming Constituents in Patients Undergoing CPB Assisted Cardiac Surgery: HES 130/0.4 or Albumin 5%

Withdrawn
NCT03373318Phase 4

Influence of Albumin on Acute Renal Dysfunction Associated With Cardiac Surgery Under Extracorporeal Circulation

Unknown
NCT02401490Phase 4

Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
26